Key result
Biologics for cardiovascular diseases face intrinsic and disease-specific limitations that currently restrict their clinical use.
Why the study?
Biologics are revolutionizing chronic disease treatment, but their clinical use remains limited for cardiovascular diseases despite being the leading cause of morbidity and mortality worldwide.
This review provides a framework for understanding the challenges of developing and applying biologic therapies in cardiovascular disease.
Clinicians should not yet use biologics for cardiovascular disease; leaves open targeted research to overcome intrinsic barriers.
Biologics are revolutionizing the treatment of chronic diseases, such as cancer and monogenic disorders, by overcoming the limits of classic therapeutic approaches using small molecules. However, the clinical use of biologics is limited for cardiovascular diseases (CVDs) , which are the primary cause of morbidity and mortality worldwide. Here, we review the state-of-the-art use of biologics for cardiac disorders and provide a framework for understanding why they still struggle to enter the field. Some limitations are common and intrinsic to all biological drugs, whereas others depend on the complexity of cardiac disease. In our opinion, delineating these struggles will be valuable in developing and accelerating the approval of a new generation of biologics for CVDs.
No takes yet. Share an insight, caveat, or question.
Ciucci et al. (2022) conducted a review in Cardiovascular diseases. Biologics was evaluated. Biologics for cardiovascular diseases face intrinsic and disease-specific limitations that currently restrict their clinical use.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: